References
- 1Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020 Apr; 16(4):223–37. DOI: 10.1038/s41581-019-0244-2
- 2Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet. 2021 Sep; 398(10304):957–80.
- 3Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013 Sep 4; 310(9):959–68. DOI: 10.1001/jama.2013.184182
- 4Schutte A, Srinivasapura Venkateshmurthy N, Mohan S, Prabakaran D. Hypertension in low- and middle-income countries [Internet]. [cited 2022 Nov 14]. Available from:
https://www.ahajournals.org/doi/epub/10.1161/CIRCRESAHA.120.318729 . - 5De Backer T, Van Nieuwenhuyse B, De Bacquer D. Antihypertensive treatment in a general uncontrolled hypertensive population in Belgium and Luxembourg in primary care: therapeutic inertia and treatment simplification. The SIMPLIFY study. PLoS ONE. 2021 Apr 5; 16(4):
e0248471 . DOI: 10.1371/journal.pone.0248471 - 6Guerrero-García C, Rubio-Guerra AF. Combination therapy in the treatment of hypertension. Drugs Context. 2018 Jun 6; 7:
212531 . DOI: 10.7573/dic.212531 - 7Milman T, Joundi RA, Alotaibi NM, Saposnik G. Clinical inertia in the pharmacological management of hypertension: a systematic review and meta-analysis. Med Baltim. 2018; 97(25):e11121–e11121. DOI: 10.1097/MD.0000000000011121
- 8Escobar C, Barrios V, Alonso-Moreno FJ, Prieto MA, Valls F, Calderon A, et al. Evolution of therapy inertia in primary care setting in Spain during 2002–2010. J Hypertens. 2014 May; 32(5):1138–45. DOI: 10.1097/HJH.0000000000000118
- 9Castro-Dominguez Y, Trejo Paredes MC, Mones P, Spatz ES, Lombo B, Sepulveda P, et al. Patient awareness and clinical inertia: obstacles to hypertension control in rural communities in the Dominican Republic. Am J Hypertens. 2021 Sep 22; 34(9):939–47. DOI: 10.1093/ajh/hpab054
- 10Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015 May 1; 175(5):
827 . DOI: 10.1001/jamainternmed.2015.0324 - 11Du L, Cheng Z, Zhang Y, Li Y, Mei D. The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis. J Clin Hypertens. 2018 Apr 27; 20(5):902–7. DOI: 10.1111/jch.13272
- 12Burnier M, Egan BM. Adherence in Hypertension. Circulation Research. 2019 March; 124(7):1124–1140. DOI: 10.1161/CIRCRESAHA.118.313220
- 13Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013 Oct 7; 34(38):2940–8. DOI: 10.1093/eurheartj/eht295
- 14Parati G, Lombardi C, Pengo M, Bilo G, Ochoa JE. Current challenges for hypertension management: from better hypertension diagnosis to improved patients’ adherence and blood pressure control. Int J Cardiol. 2021 May; 331:262–9. DOI: 10.1016/j.ijcard.2021.01.070
- 15Wang N, Salam A, Webster R, de Silva A, Guggilla R, Stepien S, et al. Association of low-dose triple combination therapy with therapeutic inertia and prescribing patterns in patients with hypertension. JAMA Cardiol. 2020 Nov; 5(11):1219–26. DOI: 10.1001/jamacardio.2020.2739
- 16Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013 Sep 4; 310(9):918–29. DOI: 10.1001/jama.2013.277064
- 17O’Hagan E, McIntyre D, Nguyen T, Chow C. Hypertension therapy using fixed-dose polypills that contain at least three medications. Heart. 2023; 109(17):1273–1280. DOI: 10.1136/heartjnl-2022-321496
- 18Wang N, Von Huben A, Marschner S, Nelson M, Nolde JM, Schlaich MP, et al. Therapeutic inertia in people receiving initial ultra low-quadruple dose combination therapy and standard dose monotherapy: results from the QUARTET trial. Hypertension. 2024; 81(5):1087–1094. DOI: 10.1161/hypertensionaha.123.22284
- 19Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018 May 15; 71(19):e127–248. DOI: 10.1016/j.jacc.2017.11.006
- 20Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal of Hypertension. 2023 Dec; 41(12):1874–2071. DOI: 10.1097/HJH.0000000000003480
- 21DiPette DJ, Skeete J, Ridley E, Campbell NRC, Lopez-Jaramillo P, Kishore SP, et al. Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: clinical perspective and policy implications. J Clin Hypertens. 2018 Nov 27; 21(1):4–15. DOI: 10.1111/jch.13426
- 22Derington CG, King JB, Herrick JS, Shimbo D, Kronish IM, Saseen JJ, et al. Trends in antihypertensive medication monotherapy and combination use among US adults, National Health and Nutrition Examination Survey 2005–2016. Hypertens Dallas Tex 1979. 2020 Apr; 75(4):973–81. DOI: 10.1161/HYPERTENSIONAHA.119.14360
- 23Salam A, Huffman MD, Kanukula R, Hari Prasad E, Sharma A, Heller DJ, et al. Two-drug fixed-dose combinations of blood pressure-lowering drugs as WHO essential medicines: an overview of efficacy, safety, and cost. J Clin Hypertens Greenwich Conn. 2020 Oct; 22(10):1769–79. DOI: 10.1111/jch.14009
- 24World Bank Country and Lending Groups – World Bank Data Help Desk [Internet]. [cited 2024 Jan 15]. Available from:
https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups . - 25OSF: POPPI-Perspectives on Polypill Prescribing Internationally [Internet]. [cited 2024 Jan 15]. Available from:
https://osf.io/nbypu/ . - 26Qualtrics Survey: Qualtrics Experience Management [Internet]. [cited 2023 Jan 24]. Available from:
https://sydney.au1.qualtrics.com/jfe/form/SV_d4JbtBbNqOuBndY . - 27Ferrari P; the National Coordinators for the Reasons for not Intensifying Antihypertensive Treatment (RIAT) trial. Reasons for therapeutic inertia when managing hypertension in clinical practice in non-Western countries. J Hum Hypertens. 2009 Mar; 23(3):151–9. DOI: 10.1038/jhh.2008.117
- 28Elnaem MH, Mosaad M, Abdelaziz DH, Mansour NO, Usman A, Elrggal ME, et al. Disparities in prevalence and barriers to hypertension control: a systematic review. Int J Environ Res Public Health. 2022 Nov 6; 19(21):
14571 . DOI: 10.3390/ijerph192114571 - 29Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016 Aug 9; 134(6):441–50. DOI: 10.1161/CIRCULATIONAHA.115.018912
- 30Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014 Dec; 4(12):
e006544 . DOI: 10.1136/bmjopen-2014-006544 - 31Howard M, Bernard C, Klein D, Elston D, Tan A, Slaven M, et al. Barriers to and enablers of advance care planning with patients in primary care. Can Fam Physician. 2018 Apr; 64(4):e190–8.
- 32Parkinson A, Jorm L, Douglas KA, Gee A, Sargent GM, Lujic S, et al. Recruiting general practitioners for surveys: reflections on the difficulties and some lessons learned. Aust J Prim Health. 2015; 21(2):
254 . DOI: 10.1071/PY13129 - 33Hutchinson MK, Sutherland MA. Conducting surveys with multidisciplinary health care providers: current challenges and creative approaches to sampling, recruitment, and data collection. Res Nurs Health. 2019; 42(6):458–66. DOI: 10.1002/nur.21976
- 34Barnhart BJ, Reddy SG, Arnold GK. Remind me again: physician response to web surveys: the effect of email reminders across 11 opinion survey efforts at the American Board of Internal Medicine from 2017 to 2019. Eval Health Prof. 2021 Sep; 44(3):245–59. DOI: 10.1177/01632787211019445
- 35Maneesriwongul W, Dixon JK. Instrument translation process: a methods review. J Adv Nurs. 2004; 48(2):175–86. DOI: 10.1111/j.1365-2648.2004.03185.x
- 36Walli-Attaei M, Joseph P, Johansson I, Sliwa K, Lonn E, Maggioni AP, et al. Characteristics, management, and outcomes in women and men with congestive heart failure in 40 countries at different economic levels: an analysis from the Global Congestive Heart Failure (G-CHF) registry. Lancet Glob Health [Internet]. 2024 Jan 10 [cited 2024 Jan 15]. Available from:
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(23)00557-0/fulltext . - 37R: The R Project for Statistical Computing [Internet]. [cited 2022 Oct 14]. Available from:
https://www.r-project.org/ . - 38Chow CK, Nguyen TN, Marschner S, Diaz R, Rahman O, Avezum A, et al. Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries. BMJ Glob Health. 2020 Nov; 5(11):
e002640 . DOI: 10.1136/bmjgh-2020-002640 - 39Attaei MW, Khatib R, McKee M, Lear S, Dagenais G, Igumbor EU, et al. Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet Public Health. 2017 Sep; 2(9):e411–9.
- 40Lung T, Jan S, De Silva HA, Guggilla R, Maulik PK, Naik N, et al. Fixed-combination, low-dose, triple-pill antihypertensive medication versus usual care in patients with mild-to-moderate hypertension in Sri Lanka: a within-trial and modelled economic evaluation of the TRIUMPH trial. Lancet Glob Health. 2019 Oct; 7(10):e1359–66. DOI: 10.1016/S2214-109X(19)30343-2
- 41Atkins ER, Chye A, Lung T, Nolde JM, Billot L, Burke M, et al. Cost-effectiveness of ultra-low-dose quadruple combination therapy for high blood pressure. Heart. 2023 Jul 26; heartjnl-2022-322300.
- 42Nguyen LH, Bruyn E, Webster R, Murphy A, Perel P, Schutte AE. Are we there yet? Exploring the use of single-pill combination therapy in the management of raised blood pressure in Australia. Heart Lung Circ. 2022 Jul; 31(7):954–63. DOI: 10.1016/j.hlc.2022.01.010
- 43Dusetzina SB, Besaw RJ, Whitmore CC, Mattingly TJ, Sinaiko AD, Keating NL, et al. Cost-related medication nonadherence and desire for medication cost information among adults aged 65 years and older in the US in 2022. JAMA Netw Open. 2023 May 18; 6(5):
e2314211 . DOI: 10.1001/jamanetworkopen.2023.14211 - 44Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PLoS Med. 2007 Sep; 4(9):
e283 . DOI: 10.1371/journal.pmed.0040283 - 45O’Connor PJ, Sperl-Hillen JM, Johnson PE, Rush WA, Biltz G. Clinical inertia and outpatient medical errors. Clin Inertia. 2:
16 . - 46O’Hagan ET, Leake HB, Heathcote LC, Stanton TR, Moseley GL. The therapeutic alliance may yet prove effective. J Orthop Sports Phys Ther. 2021 Oct; 51(10):526–7. DOI: 10.2519/jospt.2021.0203
- 47O’Hagan ET, Traeger AC, Bunzli S, Leake HB, Schabrun SM, Wand BM, et al. What do people post on social media relative to low back pain? A content analysis of Australian data. Musculoskelet Sci Pract. 2021 Aug; 54:
102402 . DOI: 10.1016/j.msksp.2021.102402 - 48Parati G, Stergiou GS, Bilo G, Kollias A, Pengo M, Ochoa JE, et al. Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. J Hypertens. 2021 Sep 1; 39(9):1742–67.
- 49Schutte AE, Kollias A, Stergiou G. Blood pressure and its variability: classic and novel measurement techniques. Nat Rev Cardiol. 2022 Apr 19; (19):643–54. DOI: 10.1038/s41569-022-00690-0
- 50Morton K, Dennison L, Band R, Stuart B, Wilde L, Cheetham-Blake T, et al. Implementing a digital intervention for managing uncontrolled hypertension in Primary Care: a mixed methods process evaluation. Implement Sci. 2021 Dec; 16(1):
57 . DOI: 10.1186/s13012-021-01123-1 - 51Huebschmann AG, Mizrahi T, Soenksen A, Beaty BL, Denberg TD. Reducing clinical inertia in hypertension treatment: a pragmatic randomized controlled trial. J Clin Hypertens. 2012 Mar 16; 14(5):322–9. DOI: 10.1111/j.1751-7176.2012.00607.x
- 52Haff N, Sreedhara SK, Wood W, Yom-Tov E, Horn DM, Hoover M, et al. Testing interventions to reduce clinical inertia in the treatment of hypertension: rationale and design of a pragmatic randomized controlled trial. Am Heart J. 2024 Feb; 268:18–28. DOI: 10.1016/j.ahj.2023.11.005
- 53Campbell NRC, Ordunez P, Giraldo G, Morales YAR, Lombardi C, Khan T, et al. WHO HEARTS: a global program to reduce cardiovascular disease burden: experience implementing in the Americas and opportunities in Canada. Can J Cardiol. 2021 May 1; 37(5):744–55. DOI: 10.1016/j.cjca.2020.12.004
- 54Khan T, Moran AE, Perel P, Whelton PK, Brainin M, Feigin V, et al. The HEARTS partner forum—supporting implementation of HEARTS to treat and control hypertension. Front Public Health. 2023 Jul 24; 11:
1146441 . DOI: 10.3389/fpubh.2023.1146441 - 55Konstantinidis D, Iliakis P, Tatakis F, Thomopoulos K, Dimitriadis K, Tousoulis D, et al. Wearable blood pressure measurement devices and new approaches in hypertension management: the digital era. J Hum Hypertens. 2022 Nov; 36(11):945–51. DOI: 10.1038/s41371-022-00675-z
- 56Kumar N, Khunger M, Gupta A, Garg N. A content analysis of smartphone–based applications for hypertension management. J Am Soc Hypertens. 2015 Feb 1; 9(2):130–6. DOI: 10.1016/j.jash.2014.12.001
- 57Parati G, Torlasco C, Omboni S, Pellegrini D. Smartphone applications for hypertension management: a potential game-changer that needs more control. Curr Hypertens Rep. 2017 May 13; 19(6):
48 . DOI: 10.1007/s11906-017-0743-0 - 58Lu X, Yang H, Xia X, Lu X, Lin J, Liu F, et al. Interactive mobile health intervention and blood pressure management in adults. Hypertension. 2019 Sep; 74(3):697–704. DOI: 10.1161/HYPERTENSIONAHA.119.13273
- 59Machnicki G, Ong SH, Chen W, Wei ZJ, Kahler KH. Comparison of amlodipine/valsartan/hydrochlorothiazide single pill combination and free combination: adherence, persistence, healthcare utilization and costs. Curr Med Res Opin. 2015 Dec; 31(12):2287–96. DOI: 10.1185/03007995.2015.1098598
- 60Xie L, Frech-Tamas F, Marrett E, Baser O. A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy. Curr Med Res Opin. 2014 Dec; 30(12):2415–22. DOI: 10.1185/03007995.2014.964853
- 61Panjabi S, Lacey M, Bancroft T, Cao F. Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients. J Am Soc Hypertens. 2013; 7(1):46–60. DOI: 10.1016/j.jash.2012.11.001
- 62Bartlett LE, Pratt NL, Roughead EE. Prior experience with cardiovascular medicines predicted longer persistence in people initiated to combinations of antihypertensive and lipid-lowering therapies: findings from two Australian cohorts. Patient Prefer Adherence. 2018 May 16; 12:835–43. DOI: 10.2147/PPA.S150142
- 63O’Hagan ET, McIntyre D, Laranjo L. The potential for a chat-based artificial intelligence model to facilitate educational messaging on hypertension. Hypertension. 2023; (80):e128–130. DOI: 10.1161/HYPERTENSIONAHA.123.21395
- 64Qadi O, Lufumpa N, Adderley N, Bem D, Marshall T, Kokab F. Patients’ and health professionals’ attitudes and perceptions towards the initiation of preventive drugs for primary prevention of cardiovascular disease: a systematic review of qualitative studies. BJGP Open. 2020 Dec; 4(5):
bjgpopen20X101087 . DOI: 10.3399/bjgpopen20X101087 - 65Virdee SK, Greenfield SM, Fletcher K, McManus RJ, Hobbs FDR, Mant J. Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study. BMJ Open. 2013 Mar 25; 3(3):
e002498 . DOI: 10.1136/bmjopen-2012-002498